Clinical Trials in Nishinomiya, Hyōgo
11 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled138 locationsNCT06615479
Recruiting
Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
Ulcerative Colitis (UC)
Bristol-Myers Squibb150 enrolled17 locationsNCT07271069
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled497 locationsNCT06430801
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb596 enrolled185 locationsNCT07100080
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Non-small Cell Lung Cancer
Summit Therapeutics780 enrolled202 locationsNCT06767514
Recruiting
Not Applicable
TheraSphere Japan Pre-Market Study
Liver Neoplasms
Boston Scientific Corporation51 enrolled4 locationsNCT07377487
Recruiting
Phase 3
Study of Out of Specification for Tisagenlecleucel
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
Takeda268 enrolled176 locationsNCT06233461
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 2
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Ulcerative Colitis
Pfizer36 enrolled47 locationsNCT05287126
Recruiting
Phase 2
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
Hyogo Medical University25 enrolled1 locationNCT06318286